PMID- 34552649 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220426 IS - 1741-427X (Print) IS - 1741-4288 (Electronic) IS - 1741-427X (Linking) VI - 2021 DP - 2021 TI - Qingre Yiqi Method along with Oral Hypoglycemic Drugs in Treating Adults with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. PG - 4395228 LID - 10.1155/2021/4395228 [doi] LID - 4395228 AB - OBJECTIVE: To evaluate the efficacy of the Qingre Yiqi method in the treatment of type 2 diabetes mellitus (T2DM) with meta-analysis. METHOD: The randomized controlled trials (RCTs) of the Qingre Yiqi method in the treatment of T2DM in the PubMed, Medline, EMBase, Cochrane Library, Web of Science, Weipu Journal, China Knowledge Network (CNKI), and Wanfang database were conducted. Three reviewers independently conducted the screening, extracted the data, and assessed methodological quality. Data analysis was performed using Rev Man 5.3 software for statistical analysis. RESULTS: A total of 15 RCTs, including 1440 patients, were included. The results showed that compared with oral hypoglycemic drugs alone, the add-on treatment of the Qingre Yiqi method could significantly improve Chinese medicine syndrome (OR (95%CI) = 3.66 [2.47,5.42], P < 0.00001) and lower the level of HbA1c (MD (95%CI) = -0.68 [0.91, -0.45], P < 0.00001), triglyceride (TG) (MD (95%CI) = -0.38 [-0.58,-0.17], P=0.0004), low-density lipoprotein cholesterol (LDL-C) (MD (95%CI) = -0.25 [-0.37, -0.13], P < 0.0001), and total cholesterol(TC) (MD(95%CI) = -0.40[-0.67, -0.13], P=0.003). In terms of fasting blood glucose (FBG) and postprandial blood sugar (PBG), subgroup analysis showed that the baseline of FBG and the number of combined oral hypoglycemic drugs of PBG were the major sources of heterogeneity. CONCLUSION: Compared with the standard treatment, the Qingre Yiqi method along with oral hypoglycemic drugs showed the more beneficial effects for T2DM on improving TCM syndromes and reducing the blood glucose and partial lipid parameter. CI - Copyright (c) 2021 Li Jiang et al. FAU - Jiang, Li AU - Jiang L AUID- ORCID: 0000-0003-3827-2178 AD - Graduate School, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. AD - Section II of Endocrinology & Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. FAU - Wang, Shidong AU - Wang S AUID- ORCID: 0000-0002-6308-3208 AD - Section II of Endocrinology & Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. FAU - Zhao, Jinxi AU - Zhao J AUID- ORCID: 0000-0002-0593-2152 AD - Section II of Endocrinology & Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. FAU - Huang, Weijun AU - Huang W AUID- ORCID: 0000-0002-2704-4674 AD - Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. FAU - Li, Jiayue AU - Li J AD - Section II of Endocrinology & Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. FAU - Xiao, Yonghua AU - Xiao Y AD - Section II of Endocrinology & Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. FAU - Zhang, Hua AU - Zhang H AD - Section II of Endocrinology & Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. FAU - Fu, Qiang AU - Fu Q AD - Section II of Endocrinology & Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. FAU - Chen, Yu AU - Chen Y AD - Graduate School, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. FAU - Yang, Tao AU - Yang T AD - Graduate School, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. FAU - Shen, Esther Aijia AU - Shen EA AD - Graduate School, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. AD - Section II of Endocrinology & Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. FAU - Su, Guanxun AU - Su G AD - Graduate School, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. AD - Section II of Endocrinology & Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. FAU - Zhang, Yaofu AU - Zhang Y AD - Graduate School, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. AD - Section II of Endocrinology & Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. FAU - Li, Zhuang AU - Li Z AD - Graduate School, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. AD - Section II of Endocrinology & Nephropathy Department of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China. LA - eng PT - Journal Article DEP - 20210911 PL - United States TA - Evid Based Complement Alternat Med JT - Evidence-based complementary and alternative medicine : eCAM JID - 101215021 PMC - PMC8452389 COIS- The authors declare no conflicts of interest regarding the publication of this paper. EDAT- 2021/09/24 06:00 MHDA- 2021/09/24 06:01 PMCR- 2021/09/11 CRDT- 2021/09/23 06:50 PHST- 2021/06/11 00:00 [received] PHST- 2021/07/09 00:00 [revised] PHST- 2021/08/13 00:00 [accepted] PHST- 2021/09/23 06:50 [entrez] PHST- 2021/09/24 06:00 [pubmed] PHST- 2021/09/24 06:01 [medline] PHST- 2021/09/11 00:00 [pmc-release] AID - 10.1155/2021/4395228 [doi] PST - epublish SO - Evid Based Complement Alternat Med. 2021 Sep 11;2021:4395228. doi: 10.1155/2021/4395228. eCollection 2021.